Date: 2015-11-19
Type of information: Establishment of a new subsidiary in the EU
Compound: Aduro Biotech Europe
Company: Aduro Biotech (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On November 19, 2015, Aduro Biotech announced that it has established European subsidiary headquarters at the BioNovion site in Oss, Netherlands now called Aduro Biotech Europe. On October 30, 2015, Aduro acquired BioNovion, a biopharmaceutical antibody discovery and development company, to broaden its technology portfolio and increase its immunotherapy capabilities. With this new base in Europe, Aduro Biotech intends to look forward to forward to collaborating with the local European medical and business communities as the company initiates international clinical research programs. In addition to Aduro’s established LADD and CDN technologies, Aduro’s new combined offerings include the B-select monoclonal antibodies (B-select) platform, which is designed to produce first- and best-in-class agonist and antagonist monoclonal antibodies (mAbs) that may be used to create a deep pipeline of products focused on harnessing the immune system of cancer patients. Aduro is an immuno-oncology company that has multiple therapeutic platforms with the potential to yield powerful immunotherapy combinations. Monoclonal antibody expertise will remain in the Aduro Biotech Europe office in the Netherlands, which will operate as a subsidiary. Andrea van Elsas, Ph.D. and Hans van Eenennaam, Ph.D, chief scientific officer and chief operating officer of BioNovion respectively, will retain their roles and titles at Aduro Biotech Europe. Near term clinical development plans include the initiation of a global Phase 3 trial to evaluate the combination of CRS-207, a LADD-based immunotherapy, and standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma. Clinical trial sites in Europe will open in 2016.
Financial terms:
Latest news:
